[S-8 POS] Verve Therapeutics, Inc. SEC Filing
Verve Therapeutics, Inc. ("Verve") filed Post-Effective Amendment No. 1 to five previously effective Form S-8 registration statements that in aggregate covered approximately 31.2 million shares of common stock reserved for the company鈥檚 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, Amended & Restated 2021 Employee Stock Purchase Plan, and 2024 Inducement Stock Incentive Plan.
On 25 July 2025, Verve completed its merger with Eli Lilly and Company through Ridgeway Acquisition Corporation and is now an indirect, wholly-owned Lilly subsidiary. Because Verve will no longer issue shares to the public, it has terminated all offerings under the S-8s and is deregistering any unsold shares that remained available under the equity plans. After effectiveness of these amendments, no Verve securities remain registered with the SEC pursuant to the referenced S-8 filings.
The document is purely administrative: it does not introduce new financing, earnings data, or changes to plan terms. It simply formalises the cleanup of outstanding share registrations following the closing of the Lilly transaction.
Verve Therapeutics, Inc. ("Verve") ha presentato l'Emendamento Post-Efficacia n. 1 a cinque dichiarazioni di registrazione Form S-8 precedentemente efficaci, che complessivamente coprivano circa 31,2 milioni di azioni ordinarie riservate per il Piano di Incentivi Azionari 2018, il Piano di Incentivi Azionari 2021, il Piano di Acquisto Azionario per Dipendenti 2021 Modificato e Ristabilito e il Piano di Incentivi Azionari di Induzione 2024.
Il 25 luglio 2025, Verve ha completato la fusione con Eli Lilly and Company tramite Ridgeway Acquisition Corporation ed 猫 ora una controllata indiretta interamente posseduta da Lilly. Poich茅 Verve non emetter脿 pi霉 azioni al pubblico, ha terminato tutte le offerte ai sensi dei moduli S-8 ed 猫 in procinto di cancellare la registrazione delle azioni invendute ancora disponibili nei piani azionari. Dopo l'efficacia di questi emendamenti, non risultano pi霉 titoli Verve registrati presso la SEC in base ai moduli S-8 indicati.
Il documento 猫 di natura puramente amministrativa: non introduce nuovi finanziamenti, dati sugli utili o modifiche ai termini dei piani. Semplicemente formalizza la pulizia delle registrazioni azionarie residue a seguito della chiusura dell'operazione con Lilly.
Verve Therapeutics, Inc. ("Verve") present贸 la Enmienda Post-Efectiva N.潞 1 a cinco declaraciones de registro Formulario S-8 previamente vigentes, que en conjunto cubr铆an aproximadamente 31,2 millones de acciones ordinarias reservadas para el Plan de Incentivos de Acciones 2018, el Plan de Incentivos de Acciones 2021, el Plan Modificado y Reestablecido de Compra de Acciones para Empleados 2021 y el Plan de Incentivos de Acciones por Inducci贸n 2024.
El 25 de julio de 2025, Verve complet贸 su fusi贸n con Eli Lilly and Company a trav茅s de Ridgeway Acquisition Corporation y ahora es una subsidiaria indirecta de propiedad total de Lilly. Dado que Verve ya no emitir谩 acciones al p煤blico, ha terminado todas las ofertas bajo los formularios S-8 y est谩 dado de baja cualquier acci贸n no vendida que quedaba disponible bajo los planes accionarios. Tras la efectividad de estas enmiendas, no quedan valores de Verve registrados en la SEC conforme a los formularios S-8 mencionados.
El documento es puramente administrativo: no introduce nuevos financiamientos, datos de ganancias ni cambios en los t茅rminos de los planes. Simplemente formaliza la limpieza de las registraciones de acciones pendientes tras el cierre de la transacci贸n con Lilly.
Verve Therapeutics, Inc.("Verve")電� 鞚挫爠鞐� 須牓鞚� 鞛堨棃雿� 雼れ劘 瓯挫潣 Form S-8 霌彪靹滊鞐� 雽�頃� 靷泟須牓 靾橃爼靹� 1順鸽ゼ 鞝滌稖頄堨溂氅�, 鞚� 靹滊霌れ潃 齑� 鞎� 3,120毵� 欤�鞚� 氤错喌欤茧ゼ 須岇偓鞚� 2018雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 2021雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 臧滌爼 氚� 鞛爼牍勲悳 2021雲� 歆侅洂 欤检嫕 甑Г 頂岆灉, 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 頂岆灉鞐� 鞓堨暯頃� 霊愳棃鞀惦媹雼�.
2025雲� 7鞗� 25鞚�, Verve電� Ridgeway Acquisition Corporation鞚� 韱淀暣 Eli Lilly and Company鞕� 頃╇硲鞚� 鞕勲頄堨溂氅� 順勳灛電� Lilly鞚� 臧勳爲 鞕勳爠 鞛愴殞靷瀰雼堧嫟. Verve臧� 雿� 鞚挫儊 雽�欷戩棎瓴� 欤检嫕鞚� 氚滍枆頃橃 鞎婈赴 霑岆鞐�, S-8鞐� 霐半ジ 氇摖 瓿惦毳� 膦呺頃橁碃 欤检嫕 頂岆灉鞐� 霐半澕 雮晞 鞛堧崢 氙疙寪毵� 欤检嫕鞚� 霌彪鞚� 毵愳唽頃橁碃 鞛堨姷雼堧嫟. 鞚� 靾橃爼靹滉皜 須牓鞚� 氚滌儩頃� 頉勳棎電�, 彀胳“霅� S-8 霌彪鞐� 霐半澕 Verve 歃濌秾鞚� SEC鞐� 雿� 鞚挫儊 霌彪霅橃柎 鞛堨 鞎婌姷雼堧嫟.
鞚� 氍胳劀電� 靾滌爠頌� 頄夓爼鞝侅澑 瓴冹溂搿�, 靸堧鞖� 鞛愱笀 臁半嫭, 靾橃澋 雿办澊韯�, 霕愲姅 頂岆灉 臁瓣贝 氤�瓴届潉 韽暔頃橃 鞎婌姷雼堧嫟. 雼 Lilly 瓯半灅 膦呺 頉� 雮晞鞛堧崢 欤检嫕 霌彪鞚� 鞝曤Μ頃橂姅 鞝堨皑毳� 瓿奠嫕頇旐暅 瓴冹瀰雼堧嫟.
Verve Therapeutics, Inc. (芦 Verve 禄) a d茅pos茅 l鈥橝mendement Post-Efficace n掳 1 脿 cinq d茅clarations d鈥檈nregistrement Formulaire S-8 pr茅c茅demment en vigueur, couvrant au total environ 31,2 millions d鈥檃ctions ordinaires r茅serv茅es pour le Plan d鈥橧ncitations en Actions 2018, le Plan d鈥橧ncitations en Actions 2021, le Plan Modifi茅 et R茅vis茅 d鈥橝chat d鈥橝ctions Employ茅s 2021, et le Plan d鈥橧ncitations en Actions d鈥橧nduction 2024.
Le 25 juillet 2025, Verve a finalis茅 sa fusion avec Eli Lilly and Company via Ridgeway Acquisition Corporation et est d茅sormais une filiale indirecte en propri茅t茅 exclusive de Lilly. Comme Verve ne d茅livrera plus d鈥檃ctions au public, elle a mis fin 脿 toutes les offres sous les formulaires S-8 et proc猫de 脿 la radiation des actions invendues encore disponibles dans le cadre des plans d鈥檃ctions. Apr猫s l鈥檈ntr茅e en vigueur de ces amendements, aucun titre Verve n鈥檈st plus enregistr茅 aupr猫s de la SEC conform茅ment aux formulaires S-8 mentionn茅s.
Ce document est purement administratif : il n鈥檌ntroduit aucun nouveau financement, donn茅es de r茅sultats ou modification des termes des plans. Il formalise simplement le nettoyage des enregistrements d鈥檃ctions en suspens suite 脿 la cl么ture de la transaction avec Lilly.
Verve Therapeutics, Inc. (鈥濾erve鈥�) hat die Nachwirkungs盲nderung Nr. 1 zu f眉nf zuvor wirksamen Form S-8-Registrierungserkl盲rungen eingereicht, die zusammen etwa 31,2 Millionen Stammaktien abdeckten, die f眉r den Aktienanreizplan 2018, den Aktienanreizplan 2021, den ge盲nderten und neu gefassten Mitarbeiteraktienkaufplan 2021 sowie den Aktienanreizplan 2024 reserviert waren.
Am 25. Juli 2025 hat Verve die Fusion mit Eli Lilly and Company 眉ber Ridgeway Acquisition Corporation abgeschlossen und ist nun eine indirekte, hundertprozentige Tochtergesellschaft von Lilly. Da Verve keine Aktien mehr 枚ffentlich ausgeben wird, hat das Unternehmen alle Angebote unter den S-8-Formularen beendet und meldet alle unverk盲uflichen Aktien, die noch unter den Aktienpl盲nen verf眉gbar waren, ab. Nach Wirksamwerden dieser 脛nderungen sind keine Verve-Wertpapiere mehr bei der SEC unter den genannten S-8-Anmeldungen registriert.
Das Dokument ist rein administrativ: Es f眉hrt keine neuen Finanzierungen, Gewinnzahlen oder 脛nderungen der Planbedingungen ein. Es formalisierte lediglich die Bereinigung der ausstehenden Aktienregistrierungen nach Abschluss der Lilly-Transaktion.
- Merger completion with Eli Lilly confirmed, eliminating the need for separate Verve share registrations and potential equity overhang.
- None.
Insights
TL;DR: Procedural filing removes 31 M unsold S-8 shares after Lilly acquisition; no financial impact.
The post-effective amendments are standard practice once a target is folded into a parent company. All equity incentive and purchase plan shares that were previously registered but not issued are now withdrawn, eliminating any potential share overhang. No new securities are being offered, so dilution risk is moot. Because the merger closed on 25 July 2025, investors have already priced in the corporate action. Impact to remaining stakeholders (now Lilly) is negligible; the action simply tidies the SEC register.
TL;DR: Filing fulfills Rule 478 obligations; confirms Verve鈥檚 transition to private status inside Lilly.
Deregistering unsold S-8 shares demonstrates compliance with undertakings in each registration statement and avoids unnecessary reporting obligations. It signals that Verve鈥檚 standalone equity compensation programs will either be rolled into Lilly plans or settled in parent shares going forward. Corporate governance risk is minimal because the parent now controls all voting power; minority public shareholders no longer exist. The filing is therefore largely housekeeping, with no material governance or capital-structure consequences.
Verve Therapeutics, Inc. ("Verve") ha presentato l'Emendamento Post-Efficacia n. 1 a cinque dichiarazioni di registrazione Form S-8 precedentemente efficaci, che complessivamente coprivano circa 31,2 milioni di azioni ordinarie riservate per il Piano di Incentivi Azionari 2018, il Piano di Incentivi Azionari 2021, il Piano di Acquisto Azionario per Dipendenti 2021 Modificato e Ristabilito e il Piano di Incentivi Azionari di Induzione 2024.
Il 25 luglio 2025, Verve ha completato la fusione con Eli Lilly and Company tramite Ridgeway Acquisition Corporation ed 猫 ora una controllata indiretta interamente posseduta da Lilly. Poich茅 Verve non emetter脿 pi霉 azioni al pubblico, ha terminato tutte le offerte ai sensi dei moduli S-8 ed 猫 in procinto di cancellare la registrazione delle azioni invendute ancora disponibili nei piani azionari. Dopo l'efficacia di questi emendamenti, non risultano pi霉 titoli Verve registrati presso la SEC in base ai moduli S-8 indicati.
Il documento 猫 di natura puramente amministrativa: non introduce nuovi finanziamenti, dati sugli utili o modifiche ai termini dei piani. Semplicemente formalizza la pulizia delle registrazioni azionarie residue a seguito della chiusura dell'operazione con Lilly.
Verve Therapeutics, Inc. ("Verve") present贸 la Enmienda Post-Efectiva N.潞 1 a cinco declaraciones de registro Formulario S-8 previamente vigentes, que en conjunto cubr铆an aproximadamente 31,2 millones de acciones ordinarias reservadas para el Plan de Incentivos de Acciones 2018, el Plan de Incentivos de Acciones 2021, el Plan Modificado y Reestablecido de Compra de Acciones para Empleados 2021 y el Plan de Incentivos de Acciones por Inducci贸n 2024.
El 25 de julio de 2025, Verve complet贸 su fusi贸n con Eli Lilly and Company a trav茅s de Ridgeway Acquisition Corporation y ahora es una subsidiaria indirecta de propiedad total de Lilly. Dado que Verve ya no emitir谩 acciones al p煤blico, ha terminado todas las ofertas bajo los formularios S-8 y est谩 dado de baja cualquier acci贸n no vendida que quedaba disponible bajo los planes accionarios. Tras la efectividad de estas enmiendas, no quedan valores de Verve registrados en la SEC conforme a los formularios S-8 mencionados.
El documento es puramente administrativo: no introduce nuevos financiamientos, datos de ganancias ni cambios en los t茅rminos de los planes. Simplemente formaliza la limpieza de las registraciones de acciones pendientes tras el cierre de la transacci贸n con Lilly.
Verve Therapeutics, Inc.("Verve")電� 鞚挫爠鞐� 須牓鞚� 鞛堨棃雿� 雼れ劘 瓯挫潣 Form S-8 霌彪靹滊鞐� 雽�頃� 靷泟須牓 靾橃爼靹� 1順鸽ゼ 鞝滌稖頄堨溂氅�, 鞚� 靹滊霌れ潃 齑� 鞎� 3,120毵� 欤�鞚� 氤错喌欤茧ゼ 須岇偓鞚� 2018雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 2021雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 臧滌爼 氚� 鞛爼牍勲悳 2021雲� 歆侅洂 欤检嫕 甑Г 頂岆灉, 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 頂岆灉鞐� 鞓堨暯頃� 霊愳棃鞀惦媹雼�.
2025雲� 7鞗� 25鞚�, Verve電� Ridgeway Acquisition Corporation鞚� 韱淀暣 Eli Lilly and Company鞕� 頃╇硲鞚� 鞕勲頄堨溂氅� 順勳灛電� Lilly鞚� 臧勳爲 鞕勳爠 鞛愴殞靷瀰雼堧嫟. Verve臧� 雿� 鞚挫儊 雽�欷戩棎瓴� 欤检嫕鞚� 氚滍枆頃橃 鞎婈赴 霑岆鞐�, S-8鞐� 霐半ジ 氇摖 瓿惦毳� 膦呺頃橁碃 欤检嫕 頂岆灉鞐� 霐半澕 雮晞 鞛堧崢 氙疙寪毵� 欤检嫕鞚� 霌彪鞚� 毵愳唽頃橁碃 鞛堨姷雼堧嫟. 鞚� 靾橃爼靹滉皜 須牓鞚� 氚滌儩頃� 頉勳棎電�, 彀胳“霅� S-8 霌彪鞐� 霐半澕 Verve 歃濌秾鞚� SEC鞐� 雿� 鞚挫儊 霌彪霅橃柎 鞛堨 鞎婌姷雼堧嫟.
鞚� 氍胳劀電� 靾滌爠頌� 頄夓爼鞝侅澑 瓴冹溂搿�, 靸堧鞖� 鞛愱笀 臁半嫭, 靾橃澋 雿办澊韯�, 霕愲姅 頂岆灉 臁瓣贝 氤�瓴届潉 韽暔頃橃 鞎婌姷雼堧嫟. 雼 Lilly 瓯半灅 膦呺 頉� 雮晞鞛堧崢 欤检嫕 霌彪鞚� 鞝曤Μ頃橂姅 鞝堨皑毳� 瓿奠嫕頇旐暅 瓴冹瀰雼堧嫟.
Verve Therapeutics, Inc. (芦 Verve 禄) a d茅pos茅 l鈥橝mendement Post-Efficace n掳 1 脿 cinq d茅clarations d鈥檈nregistrement Formulaire S-8 pr茅c茅demment en vigueur, couvrant au total environ 31,2 millions d鈥檃ctions ordinaires r茅serv茅es pour le Plan d鈥橧ncitations en Actions 2018, le Plan d鈥橧ncitations en Actions 2021, le Plan Modifi茅 et R茅vis茅 d鈥橝chat d鈥橝ctions Employ茅s 2021, et le Plan d鈥橧ncitations en Actions d鈥橧nduction 2024.
Le 25 juillet 2025, Verve a finalis茅 sa fusion avec Eli Lilly and Company via Ridgeway Acquisition Corporation et est d茅sormais une filiale indirecte en propri茅t茅 exclusive de Lilly. Comme Verve ne d茅livrera plus d鈥檃ctions au public, elle a mis fin 脿 toutes les offres sous les formulaires S-8 et proc猫de 脿 la radiation des actions invendues encore disponibles dans le cadre des plans d鈥檃ctions. Apr猫s l鈥檈ntr茅e en vigueur de ces amendements, aucun titre Verve n鈥檈st plus enregistr茅 aupr猫s de la SEC conform茅ment aux formulaires S-8 mentionn茅s.
Ce document est purement administratif : il n鈥檌ntroduit aucun nouveau financement, donn茅es de r茅sultats ou modification des termes des plans. Il formalise simplement le nettoyage des enregistrements d鈥檃ctions en suspens suite 脿 la cl么ture de la transaction avec Lilly.
Verve Therapeutics, Inc. (鈥濾erve鈥�) hat die Nachwirkungs盲nderung Nr. 1 zu f眉nf zuvor wirksamen Form S-8-Registrierungserkl盲rungen eingereicht, die zusammen etwa 31,2 Millionen Stammaktien abdeckten, die f眉r den Aktienanreizplan 2018, den Aktienanreizplan 2021, den ge盲nderten und neu gefassten Mitarbeiteraktienkaufplan 2021 sowie den Aktienanreizplan 2024 reserviert waren.
Am 25. Juli 2025 hat Verve die Fusion mit Eli Lilly and Company 眉ber Ridgeway Acquisition Corporation abgeschlossen und ist nun eine indirekte, hundertprozentige Tochtergesellschaft von Lilly. Da Verve keine Aktien mehr 枚ffentlich ausgeben wird, hat das Unternehmen alle Angebote unter den S-8-Formularen beendet und meldet alle unverk盲uflichen Aktien, die noch unter den Aktienpl盲nen verf眉gbar waren, ab. Nach Wirksamwerden dieser 脛nderungen sind keine Verve-Wertpapiere mehr bei der SEC unter den genannten S-8-Anmeldungen registriert.
Das Dokument ist rein administrativ: Es f眉hrt keine neuen Finanzierungen, Gewinnzahlen oder 脛nderungen der Planbedingungen ein. Es formalisierte lediglich die Bereinigung der ausstehenden Aktienregistrierungen nach Abschluss der Lilly-Transaktion.
FAQ
Why did Verve Therapeutics (VERV) file these Post-Effective Amendments?
How many Verve shares are being deregistered?
Does the filing affect Verve鈥檚 public shareholders?
Are any new financial results or earnings disclosed?
What happens to Verve鈥檚 equity incentive plans after deregistration?
